Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
MNKD Transcript
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call presents mixed signals. While there is positive growth in FUROSCIX sales and strategic product launches, declines in Tyvaso DPI revenues and GAAP net losses are concerning. The Q&A reveals positive sentiment towards FUROSCIX and Afrezza growth but lacks clarity on some strategic initiatives. The market cap suggests moderate volatility, and the combination of optimistic guidance with some financial setbacks results in a neutral prediction for stock movement.
MannKind Corporation (MNKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary highlights strong financial performance, with significant revenue growth driven by Afrezza and FUROSCIX. Product development is advancing, with promising pipeline updates and strategic initiatives. Market strategy and shareholder return plans are not explicitly detailed but implied through growth projections. The Q&A session reveals optimism for future revenue growth, particularly with the pediatric segment and FUROSCIX auto-injector launch. Despite some management vagueness, the overall sentiment is positive, with potential catalysts for stock price appreciation. Considering the small-cap nature, a positive stock price movement (2% to 8%) is expected.
MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call highlights strong financial metrics, optimistic guidance, and strategic growth initiatives. The company expects significant growth in Afrezza sales and FUROSCIX, supported by investments in sales force expansion and new product developments. The strategic financing with Blackstone provides a substantial non-dilutive funding boost. Market opportunities, especially in the NTM market, are promising, and the company is confident in its pricing model. Despite some unclear management responses, the overall sentiment is positive, with potential catalysts like the Afrezza label update and ReadyFlow injector expansion.
MNKD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
